Consistent with HER2-positive breast cancer patients, the levels of plasma arachidonic acid and several fatty acid-derived acylcarnitines in HER2-negative breast cancer patients were significantly decreased 2 weeks after completion of doxorubicin treatment (Table 2; Additional file 1: Table S5). This evidence concerns the gene ERBB2 and breast carcinoma.